Proteomic Analysis of Hydroxysafflor Yellow A Against Cerebral Ischemia/Reperfusion Injury in Rats
Proteomic Analysis of Hydroxysafflor Yellow A Against Cerebral Ischemia/Reperfusion Injury in Rats
复制标题
羟基红花黄A抗大鼠脑缺血再灌注损伤的蛋白质组学分析
DOI：
10.1089/rej.2018.2145
复制
发表时间：
2019
影响因子：
2.6
通讯作者：
Ding Yi
中科院分区：
文献类型：
--
作者：
Xu Hang;Liu Tianlong;Wang Wenjun;Su Ning;Yang Liudi;Yang Zhifu;Dou Fang;Cui Jia;Fei Fei;Ma Jing;Wen Aidong;Ding Yi
羟基红花黄色素A（HSYA）是一种中草药活性成分，在脑缺血/再灌注损伤（CIRI）的防治中有着广泛的应用。为了阐明HSYA治疗中风的全面机制，我们使用无标记定量蛋白质组学分析来研究CIRI大鼠的调节蛋白以及HSYA对其的改变。通过神经系统检查、脑梗死评估和生化检测来验证HSYA的作用，结果表明HSYA具有明显的脑保护作用。通过无标记定量蛋白质组学分析，共鉴定出13个重叠蛋白。基因本体和途径分析表明，这些差异表达蛋白主要富集在缺氧诱导因子1（HIF-1）信号通路中。此外，网络的构建与蛋白质功能的相互作用。结果表明，在模型组和假手术组之间，有7个蛋白被鉴定为枢纽蛋白，而在HSYA组和模型组之间，有25个蛋白被鉴定为枢纽蛋白。此外，三种重叠蛋白的表达经过蛋白质印迹验证，其水平与无标记分析结果一致。总之，通过蛋白质组学分析，Eftud 2、mTOR、Rab 11、Ppp 2 r5 e和HIF-1信号通路已被检测为HSYA抗CIRI的关键枢纽蛋白和通路。我们的研究为HSYA抗CIRI的机制提供了令人信服的解释，所鉴定的关键蛋白和途径可能为CIRI提供新的治疗方法。
Hydroxysafflor yellow A (HSYA), an active component from Chinese medicinal herb, has been applied to the prevention and treatment of cerebral ischemia/reperfusion injury (CIRI). To clarify the comprehensive mechanisms HSYA for stroke, we used label-free quantitative proteomic analysis to investigate the modulated proteins of rats subjected to CIRI and their alteration by HSYA. Neurological examination, infarct assessment, and biochemical assay were performed to validate the effects of HSYA, and the results indicated that HSYA played a significant role in brain protection. A total of 13 proteins were identified as overlapped proteins by label-free quantitative proteomic analysis. Gene Ontology and pathway analysis showed that these differentially expressed proteins were mainly enriched in the hypoxia-inducible factor 1 (HIF-1) signaling pathway. Furthermore, networks were constructed with respect to protein function interactions. The results suggested that seven proteins were identified as hub proteins between model and sham groups, while 25 proteins were identified as hub proteins between HSYA and model groups. In addition, the expressions of three overlapping proteins were validated by Western blot, and their levels were consistent with the results of label-free analysis. In conclusion, Eftud2, mTOR, Rab11, Ppp2r5e, and HIF-1 signaling pathways have been detected as key hub proteins and pathways in HSYA against CIRI through proteomic analysis. Our research has provided convincing explanations for the mechanism of HSYA against CIRI and the identified key proteins and pathways might provide novel therapeutics for CIRI.